Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab and Irinotecan in Advanced Esophageal Adenocarcinoma
NCT00836277Phase 2Completed
- Start
- May 2009
- Primary completion
- Aug 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in esophageal adenocarcinoma (EAC). Started May 2009; status: completed.
02
Drugs
panitumumab
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT00836277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00836277.